Key Takeaway: Kura Oncology, a biopharmaceutical company focused on precision cancer treatments, announced its participation in three upcoming investor conferences. The conferences include the TD Cowen Health Care Conference, the Leerink Partners Global Biopharma Conference, and the Barclays Global Healthcare Conference, all scheduled for March 2026. Live audio webcasts will be available on Kura's website.
Price reaction · baseline $8.38 (2026-02-24 close) · hit pre-market · 1 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Kura Oncology is actively engaging with investors.
Participation in multiple high-profile conferences.
Focus on precision medicines for cancer treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic
Full Press Release Details
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences:
TD Cowen Health Care ConferenceMarch 4, 202611:50 a.m. ET / 8:50 a.m. PT
Leerink Partners Global Biopharma ConferenceMarch 10, 202610:40 a.m. ET / 7:40 a.m. PT
Barclays Global Healthcare ConferenceMarch 12, 20269:00 a.m. ET / 6:00 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website athttps://kuraoncology.com/, with archived replays available following all three events.
About Kura OncologyKura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractoryNPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website athttps://kuraoncology.com/and follow us onXandLinkedIn.
Kura Contact
Frequently Asked Questions
What investor conferences is Kura Oncology attending?
Kura Oncology will attend the TD Cowen, Leerink Partners, and Barclays conferences.
When are the Kura Oncology investor conferences scheduled?
The conferences are scheduled for March 4, 10, and 12, 2026.
Where can I find the webcasts of Kura's conferences?
Live webcasts will be available on Kura's website in the Investors section.
What is Kura Oncology's focus?
Kura Oncology focuses on precision medicines for cancer treatment.